EUVIMEDEUVIMED entdecken
Crossref

Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMML

Jian-Ying Zhou iD, Song Wang iD, Hai-Long Yuan, Ya-Jing Xu, Xiao-Bing Huang, Su-Jun Gao, Yi-Cheng Zhang, Fang Zhou, Yue Liu, Xian-Min Song, Yu Cai, Xiao-Liang Liu und 48 weitere

American Journal of Hematology · 2023-09 · 98 (9) · 1394-1406

DOI: 10.1002/ajh.26999 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 27.06.2023. Verfasst von Jian-Ying Zhou und 59 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Leukemia, Myelomonocytic, Chronic, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: Capital Health Research and Development of Special Fund, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell malignancy, and allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is the only curable treatment. The outcomes after transplant are influenced by both disease characteristics and patient comorbidities. To develop a novel prognostic model to predict the post‐transplant survival of CMML patients, we identified risk factors by applying univariable and multivariable Cox proportional hazards regression to a derivation cohort. In multivariable analysis, advanced age (hazard ratio [HR] 3.583), leukocyte count (HR 3.499), anemia (HR 3.439), bone marrow blast cell count (HR 2.095), and no chronic graft versus host disease (cGVHD; HR 4.799) were independently associated with worse survival. A novel prognostic model termed ABLAG (Age, Blast, Leukocyte, Anemia, cGVHD) was developed and the points were assigned according to the regression equation. The patients were categorized into low risk (0–1), intermediate risk (2, 3), and high risk (4–6) three groups and the 3‐year overall survival (OS) were 93.3% (95%CI, 61%–99%), 78.9% (95%CI, 60%–90%), and 51.6% (95%CI, 32%–68%; p < .001), respectively. In internal and external validation cohort, the area under the receiver operating characteristic (ROC) curves of the ABLAG model were 0.829 (95% CI, 0.776–0.902) and 0.749 (95% CI, 0.684–0.854). Compared with existing models designed for the nontransplant setting, calibration plots, and decision curve analysis showed that the ABLAG model revealed a high consistency between predicted and observed outcomes and patients could benefit from this model. In conclusion, combining disease and patient characteristic, the ABLAG model provides better survival stratification for CMML patients receiving allo‐HSCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelomonocytic, ChronicHematopoietic Stem Cell TransplantationGraft vs Host DiseaseHumansPrognosisTransplantation, HomologousRetrospective Studies

Autor:innen und Institutionen

  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, Chin…
  • Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
  • Department of Hematology, Xiangya Hospital of Central South University, Changsha, China.
  • Department of Hematology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
  • Hematology Section, Cancer Center, The First Hospital of Jilin University, Changchun, China.
  • Department of Hematology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.

ORCID-Profile: Jian-Ying Zhou, Song Wang, Yi Luo, Jian-Min Yang, Yi-Mei Feng

Förderung

  • Capital Health Research and Development of Special Fund
  • National Key Research and Development Program of China

Zitieren

APA

Zhou, J. Y., Wang, S., Yuan, H. L., Xu, Y. J., Huang, X. B., Gao, S. J., Zhang, Y. C., Zhou, F., Liu, Y., Song, X. M., Cai, Y., Liu, X. L., Luo, Y., Yang, L. X., Yang, J. M., Wang, L. B., Li, Y. H., Huang, R., Wang, S. Q., …, & Han, W. (2023). Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMML. American Journal of Hematology, 98(9), 1394-1406. https://doi.org/10.1002/ajh.26999

Vancouver

Zhou JY, Wang S, Yuan HL, Xu YJ, Huang XB, Gao SJ, et al. Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMML. American Journal of Hematology. 2023;98(9):1394-1406. doi:10.1002/ajh.26999

BibTeX
@article{Zhou2023,
  author = {Zhou, Jian-Ying and Wang, Song and Yuan, Hai-Long and Xu, Ya-Jing and Huang, Xiao-Bing and Gao, Su-Jun and Zhang, Yi-Cheng and Zhou, Fang and Liu, Yue and Song, Xian-Min and Cai, Yu and Liu, Xiao-Liang and Luo, Yi and Yang, Lu-Xin and Yang, Jian-Min and Wang, Li-Bing and Li, Yu-Hua and Huang, Rui and Wang, Shun-Qing and Zhou, Ming and Dong, Yu-Jun and Wang, Qian and Zhang, Xi and Feng, Yi-Mei and Du, Xin and Ling, Wei and Zhu, Han and Zhu, Zun-Min and Chen, Xiang-Li and Wang, Shi-Yu and Meng, Fan-Kai and Bi, Ke-Hong and Huang, Ning and Jiang, Ming and Niu, Ting and Ji, Jie and Wan, Ding-Ming and Bian, Zhi-Lei and Chen, Yi and Liu, Li and Yan, Xue-Qian and Yang, Xi and Yi, Hai and Wei, Xu-Dong and Li, Xin and Cheng, Qian and Yuan, Cheng-Lu and Wang, Wen and Zhou, Yu-Hong and Ye, Bao-Dong and Ding, Jing and Wu, Ye-Jun and Huang, Qiu-Sha and Zhu, Xiao-Lu and Chen, Yu-Hong and He, Yun and Wang, Feng-Rong and Zhang, Yuan-Yuan and Mo, Xiao-Dong and Han, Wei},
  title = {Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMML},
  journal = {American Journal of Hematology},
  year = {2023},
  volume = {98},
  number = {9},
  pages = {1394--1406},
  doi = {10.1002/ajh.26999}
}
Kostenlos starten →